Relmada Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Relmada Therapeutics, Inc. (Nasdaq: RLMD) is a clinical-stage biotechnology company focused on developing innovative therapies for central nervous system (CNS) disorders and oncology. Historically, the company's primary focus was esmethadone (REL-1017), an NMDA receptor channel blocker developed for major depressive disorder (MDD). Following disappointing clinical trial results for REL-1017 in late 2024, Relmada executed a major strategic pivot in early 2025. The company acquired sepranolone, a Phase 2b-ready neurosteroid targeting Prader-Willi syndrome (PWS) and other GABAergic-related disorders, and in-licensed NDV-01, a novel sustained-release intravesical formulation of gemcitabine/docetaxel for non-muscle invasive bladder cancer (NMIBC).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Following a comprehensive strategic review in late 2024 and early 2025, Relmada terminated its legacy esmethadone and psilocybin programs. The company redirected its resources toward late-stage, de-risked assets in oncology and rare CNS disorders.
Expected impact: Mitigates clinical development risk, establishes a diversified pipeline with multiple registrational pathways, and targets high-value indications with significant unmet medical needs.
Developing NDV-01, a novel sustained-release intravesical formulation of gemcitabine and docetaxel, for two distinct indications: high-risk second-line BCG-unresponsive NMIBC and intermediate-risk adjuvant NMIBC.
Expected impact: Aims to establish a best-in-class, bladder-sparing therapeutic option for patients who have failed first-line therapies, addressing a market of approximately 5,000 patients annually in the U.S..
Advancing sepranolone, a novel neurosteroid epimer of allopregnanolone, into clinical trials for compulsivity-related disorders, starting with a Phase 2 study in Prader-Willi syndrome (PWS).
Expected impact: Addresses a rare genetic disorder affecting 350,000–400,000 people globally, targeting compulsive behaviors such as hyperphagia.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquired the asset sepranolone, a novel neurosteroid epimer of allopregnanolone, to expand Relmada's pipeline into rare CNS and compulsivity-related disorders. The transaction aligns with Relmada's mission to address difficult-to-treat CNS disorders and leverage its core drug development competencies.
Financial impact: The asset purchase was completed for an upfront payment of EUR 3 million (approximately USD 3.25 million).
Strategic Partnerships
Secured exclusive worldwide rights (excluding Israel, India, and South Africa) to NDV-01, a novel sustained-release intravesical formulation of gemcitabine and docetaxel for the treatment of non-muscle invasive bladder cancer (NMIBC) [2.1.3]. This partnership forms the cornerstone of Relmada's oncology pipeline.
Terms: Relmada paid an upfront license fee of $3.5 million and issued 3,017,420 restricted shares of common stock (representing 10% of outstanding shares at the time). The agreement includes up to $105 million in development/regulatory milestones, up to $95 million in commercial milestones, and a 3% royalty on net sales in the licensed territory.